Unlike ConocoPhillips (COP), Hess’s (HES) dividend wasn’t big enough to move the needle if cut. So it’s selling stock instead:
Hess has priced the concurrent offering of ~28.8mm shares of common stock and ~11.5mm depositary shares, assuming the over-allotment options are exercised. The depositary shares represent a 1/20th interest in each share of Hess 8% Mandatory Convertible Preferred Stock, which unless converted earlier at the option of the holder will convert on or around February 1st, 2019 into Hess common shares. Based on the equity offering price of $39/share, we estimate total net proceeds of ~$1.65bn net common offering proceeds of $1.09bn and net depositary share offering proceeds of ~$558mm. The offerings represent ~10% of Hess prior outstanding share count and ~15% on fully diluted basis including the conversion of the convertible preferred shares.
Top 5 Up And Coming Stocks To Buy Right Now: Canon, Inc.(CAJ)
Canon Inc. (Canon), incorporated on August 10, 1937, is a manufacturer of office multifunction devices (MFDs), plain paper copying machines, laser printers, inkjet printers, cameras and lithography equipment. Canon sells its products principally under the Canon brand name and through sales subsidiaries. The Company earns revenues primarily from the manufacture and sale of these products domestically and internationally. Canon has manufacturing subsidiaries in a variety of countries, including the United States, Germany, France, the Netherlands, Taiwan, China, Malaysia, Thailand, Vietnam and the Philippines. Canon operates its business in three segments: the Office Business Unit, the Imaging System Business Unit, and the Industry and Others Business Unit.
Office Business Unit
Canon manufactures, markets and services a range of MFDs, printers, copying machines for personal and office use and production print products for print professionals. The Off ice Business Unit includes MFDs, laser multifunction printers (MFPs), laser printers, digital production printing systems, feed printers, wide-format printers and document solutions. The Company also delivers added value to customers through software, services and solutions. Its offerings cover a range of markets from Small Office Home Office (SOHO), and Small and Midsize Business (SMB) to large enterprises and professional graphic arts. Canon has launched its A4-size color device imageRUNNER ADVANCE C350iF/C250iF. Canon has also launched imageRUNNER 2202/2002, which is a low-end A3-size monochrome device tailored to the emerging market.
In software, services and solutions, Canon’s application development platform, the Multifunctional Embedded Application Platform (MEAP), allows the creation of customized applications for Canon MFDs. Canon is engaged in reinforcing its solutions capability through offerings, such as imageWARE software suite, business process aut omation software Enterprise Imaging Platform (EIP) and Canon! MDS, which is a device management solution. Canons consolidated net sales, for the years ended December 31, 2014, were 55.8% for the Office Business Unit.
The Company competes with Xerox Corporation/Fuji Xerox Co., Ltd.; Ricoh Company, Ltd.; Konica Minolta Inc.; Hewlett-Packard Company; Samsung Electronics Co., Ltd., Toshiba TEC Corporation, Sharp Corporation and Lexmark International, Inc.
Imaging System Business Unit
Canon manufactures and markets digital cameras and digital video camcorders, as well as lenses and various related accessories. The Imaging System Business Unit includes interchangeable lens digital cameras, digital compact cameras, digital camcorders, digital cinema cameras, interchangeable lenses, inkjet printers, large-format inkjet printers, commercial photo printers, image scanners, multimedia projectors, broadcast equipment and calculators.
The Company has launched two new digital single-lens reflex camera (SLR) cameras. The Canon EOS 7D Mark II is designed to meet the demands of photographers and videographers who want a camera that can provide a range of artistic opportunities. It shoots up to 10 frames per second and has a 65-point all cross-type AF system. The number of available autofocus (AF) points, and whether single line or cross-type, varies depending on the lens. Canon also launched seven new lens products for digital SLR. The interchangeable lens lineup exceeds 90 products, including Cinema Lenses (EF-Mount).
The Company has introduced fourteen new models to the compact digital camera market across the world. Canon offers a range of products to meet needs based on its core technology Full-photolithography Inkjet Nozzle Engineering (FINE). For home use, Canon offers printer solutions as PIXMA Cloud Link and PIXMA Printing to tighten the connection with cloud computing, smartphone and tablet personal computers (PC). It also offers My Image Garden , enabling a range of photo-print, an Intelligent Touch Syst! em and XL! ink tank & ink cartridge.
Canon launched the brand MAXIFY in the business inkjet printer segment. In the professional printing market, the Company offers three professional photo inkjet printers: the PIXMA PRO-1 with a 12 LUCIA ink system of pigment-based inks, PIXMA PRO-10 with a 10 LUCIA ink system, and the PIXMA PRO-100 with eight dye inks to produce colorful and vivid prints. Canons large-format inkjet printers are based on FINE head technology and employ its image processor, L-COA, developed for LUCIA pigment inks. Canons lineup also includes CanoScan LiDE, the flatbed scanners which use Contact Image Sensor (CIS), and a scanner with Charge-Coupled Devices (CCD) for high resolution. Canons consolidated net sales, for the years ended December 31, 2014, were 36.0% for the Imaging System Business Unit.
The Company competes with Sony Corporation, Samsung Electronics Co., Ltd., Nikon Corporation; Panasonic Corporation; JVC Kenwood Corporat ion, Hewlett-Packard Company and Seiko Epson Corporation.
Industry and Others Business Unit
The Company’s Industry and Others Business Unit segment includes semiconductor lithography equipment, Flat panel display (FPD) lithography equipment, digital radiography systems, ophthalmic equipment, vacuum thin-film deposition equipment, organic light emitting diode (OLED) panel manufacturing equipment, die bonders, micromotors, network cameras, handy terminals and document scanners. Canons consolidated net sales for the years ended December 31, 2014, were 10.7% for the Industry and Others Business Unit.
The Company competes with Nikon Corporation and ASML Holding N.V.
- [By Dan Carroll]
Nikon’s story is similar to what’s plaguing its Japanese rival, Canon (NYSE: CAJ ) . Canon’s stock has nosedived by 20% year to date, but the stock’s recovered nearly 3% over the past month. Don’t let appearances fool you: The company slashed its full-year sales and profit forecasts back in July, as the worldwide camera market has slumped, and as smartphones continue to take over this aging niche. Canon’s route back to respectability looks like a treacherous climb.
- [By Paul R. La Monica]
Miscellaneous shorts. Lamensdorf is also betting against Japanese printer and camera giant Canon (CAJ) since he believes the company still hasn’t figured out a way to compete with smartphones.
Top 5 Up And Coming Stocks To Buy Right Now: Bruker Corporation(BRKR)
Bruker Corporation designs, manufactures, services, and sells proprietary life science and materials research systems worldwide. The company?s Scientific Instruments segment offers advanced instrumentation and automated solutions based on magnetic resonance, mass spectrometry, gas chromatography, X-ray, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology, and infrared and Raman molecular spectroscopy technologies. This segment serves pharmaceutical, biotechnology, and molecular diagnostic companies; academic institutions, medical schools, and other non-profit organizations; clinical microbiology laboratories; government departments and agencies; nanotechnology, semiconductor, chemical, cement, metals, and petroleum companies; and food, beverage, and agricultural analysis companies and laboratories. Its Energy & Supercon Technologies segment provides superconducting materials, including metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research, and other applications; and ceramic high temperature superconductors primarily for fusion energy research applications, as well as non-superconducting Cuponal materials and wires based on co-extruded copper and aluminum, and non-superconducting high technology tools. Its customers include companies in the medical industry; private and public research and development laboratories in the fields of fundamental and applied sciences, and energy research; academic institutions; and government agencies. This segment is also involved in the development of superconductors and superconducting-enabled devices for applications in power and energy, as well as industrial processing industries. The company markets its products through direct sales force; and distributors, independent sales representatives, and other representatives. Bruker Corporation was founded in 1991 and is headquartered in Billerica, M assachusetts.
- [By Javier Hasse]
Yet another stock experiencing a correction after the bell was Bruker Corporation (NASDAQ: BRKR), which lost 2.75 percent in after-hours, after having gained 4.5 percent during the day.
Best Oil Service Stocks For 2016: Pebblebrook Hotel Trust(PEB)
Pebblebrook Hotel Trust, through Pebblebrook Hotel, L.P., operates as a real estate investment trust. The company acquires and invests primarily in hotel properties located in the United States. It holds interests in the Doubletree Bethesda Hotel and Executive Meeting Center located in Bethesda, Maryland; Sir Francis Drake Hotel located in San Francisco, California; and InterContinental Buckhead Hotel located in Atlanta, Georgia. As a REIT, the company is not subject to federal income tax to the extent that it distributes at least 90% of its taxable income to its shareholders. The company was founded in 2009 and is based in Bethesda, Maryland.
- [By Marshall Hargrave]
The other key benefit for Strategic is that it enjoys industry-leading earnings before interest, taxes, depreciation and amortization (EBITDA) per available room. For 2012, Strategic generated $81 per room of EBITDA. Compare this to top comps LaSalle Hotel (NYSE: LHO) at $74 per room and Pebblebrook Hotel Trust (NYSE: PEB) at $71. The reason for this is that Strategic is much less reliant than its peers on rooms, with much greater exposure to food and beverages. Strategic earns 53% of its revenue from rooms, while its peers get around 66% of revenues from rooms.
Top 5 Up And Coming Stocks To Buy Right Now: Infinity Pharmaceuticals, Inc.(INFI)
Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. The company is developing DYNAMO, which is in Phase II study to evaluate the safety and efficacy of IPI-145 dosed at 25 mg; CONTEMPO that is in the Phase Ib/II study of IPI-145 in combination with obinutuzumab or rituximab in patients with untreated follicular lymphoma; BRAVURA, which is in Phase III study to evaluate the safety and efficacy of IPI-145 plus rituximab and bendamustine; and FRESCO that is in Phase II study to evaluate the safety and efficacy of IPI-145 plus rituximab. It is also developing DYNAMO+R, which is in Phase III randomized study to evaluate IPI-145 dosed at 25 mg in c ombination with rituximab, a monoclonal antibody treatment; DUO that is in randomized Phase III monotherapy study evaluating IPI-145 dosed at 25 mg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL); and SYNCHRONY, which is in the Phase Ib study of IPI-145 in combination with obinutuzumab in CLL patients. In addition, the company is conducting a Phase Ib/II trial of IPI-145 in combination with venetoclax, a B-cell lymphoma 2 inhibitor; and developing IPI-549 that is in Phase I study for patients with various solid tumors, including melanoma and non-small cell lung cancer. The company has collaboration and license agreement with AbbVie Inc. to develop and commercialize IPI-145 in oncology; and development and license agreement with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
- [By Lisa Levin]
Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares dropped 70 percent to $1.32. Infinity announced plans to cut 21 percent of the workforce. The company also reported that DYNAMO Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib met its primary endpoint.
Top 5 Up And Coming Stocks To Buy Right Now: Beazer Homes USA, Inc.(BZH)
Beazer Homes USA, Inc., incorporated on November 24, 1993, is a diversified homebuilder with operations in 16 states within three geographic regions in the United States: West, East and Southeast. The Companys homes are designed to appeal to homeowners at various price points across various demographic segments and are generally offered for sale in advance of their construction.
The Company has three homebuilding segments: West, which includes Arizona, California, Nevada and Texas; East, which includes Delaware, Indiana, Maryland, New Jersey, New York, Pennsylvania, Tennessee (Nashville) and Virginia; and Southeast, which includes Florida, Georgia, North Carolina (Raleigh) and South Carolina. The Company partners with Moen, Certain Teed and DuPont Tyvek. The Company provides information about the active communities through its Internet Website located atwww.beazer.com.
- [By Federico Zaldua]
Beazer Homes USA (BZH), the diversified home-builder which is held by Mario Gabelli from GAMCO Investors, is my top play among single-family and multi-family home builders. While I believe higher interest rates should slow the pace of margin expansion for Beazer, I also believe higher top line growth will more than compensate interest rate effects on net earnings. As a matter of fact, I think gross margins are going to go north of 17.5% by the end of 2014 while top-line should keep on growing at a rate of 25%.